Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKOSOL vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular c AMP, leading to smooth muscle relaxation in the airways.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, chronic bronchitis, emphysema)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
2.5 mg (0.5 m L of 0.5% solution) via nebulization three to four times daily, as needed.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via catechol-O-methyltransferase (COMT); also undergoes sulfate conjugation.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
40–60% bound to albumin, with some binding to alpha-1-acid glycoprotein.
55–65% bound to plasma proteins, primarily albumin.
Approximately 0.5 L/kg, indicating distribution into total body water and moderate tissue binding.
0.4–0.6 L/kg, indicating distribution into total body water.
Inhalation: 10–20% (variable due to deposition and first-pass metabolism); oral: <1% due to extensive first-pass metabolism.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No specific guidelines; use caution in severe hepatic impairment.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
0.01-0.03 m L/kg of 0.5% solution (maximum 0.5 m L) via nebulization every 4-6 hours as needed.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Initiate at lowest effective dose; monitor for tachycardia and hypertension.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects: tachycardia, hypertension, arrhythmias,Hypokalemia may occur with high doses,Caution in patients with hyperthyroidism, diabetes mellitus, or seizure disorders
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to isoetharine or any component,Cardiac arrhythmias associated with tachycardia,Tachycardia or heart block caused by digitalis intoxication
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No significant food interactions. Avoid excessive caffeine intake as it may increase beta-agonist side effects (tremor, tachycardia). No specific dietary restrictions.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
FDA Pregnancy Category C. In first trimester, limited data; animal studies show no teratogenicity at high doses. Second and third trimesters: no known fetal risks from inhaled bronchodilator use; systemic exposure minimal. However, uncontrolled asthma poses greater risk (maternal hypoxia, preterm birth).
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Excreted in breast milk in small amounts. M/P ratio not reported. Inhaled route minimizes systemic absorption; unlikely to affect nursing infant. Use with caution, weigh risks vs benefits.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No dose adjustment typically required. Pregnancy may alter asthma severity; titrate dose to achieve symptom control. Inhaled beta-2 agonists generally safe; no significant pharmacokinetic changes reported.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Bronkosol (isoetharine) is a beta-2 selective bronchodilator, but with less beta-2 selectivity than albuterol; monitor for tachycardia and tremor. It is administered via nebulization; ensure proper equipment and technique. Onset within 2-5 minutes, duration 1-3 hours. Not a first-line agent; use primarily for acute bronchospasm when albuterol is unavailable. Paradoxical bronchospasm can occur; discontinue if worsens.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,If you miss a dose, use it as soon as you remember, but skip if it's almost time for the next dose; do not double up.,Rinse your mouth with water after each use to prevent dryness and irritation.,Seek immediate medical help if symptoms worsen or you experience chest pain, fast heartbeat, or difficulty breathing after use.,Store at room temperature away from moisture and heat; keep nebulizer clean per instructions.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKOSOL vs AEROLATE SR, answered by our medical review team.
BRONKOSOL is a Bronchodilator that works by Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular c AMP, leading to smooth muscle relaxation in the airways.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKOSOL and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKOSOL is: 2.5 mg (0.5 m L of 0.5% solution) via nebulization three to four times daily, as needed.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKOSOL and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKOSOL is classified as Category C. FDA Pregnancy Category C. In first trimester, limited data; animal studies show no teratogenicity at high doses. Second and third trimesters: no known fetal risks from inhaled bron. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.